![conference banner](/images/conference-banner.jpeg)
Abstract
Bisphosphonates are standard treatment for cancer-induced bone disease, a common feature of many advanced malignancies. Traditionally used to inhibit bone turnover and reduce the risk of skeletal-related events, there is now increasing pre-clinical evidence that these agents may also affect tumour burden and disease progression. In particular, combining bisphosphonates with chemotherapeutic agents has been demonstrated to cause substantially increased anti-tumour effects compared to giving the single agents. Clinical studies are in progress to determine whether adding bisphosphonates to standard anti-cancer therapy results in improved outcome for patients. Here we give an overview of the key pre-clinical studies of anti-tumour effects of bisphosphonates, alone and in combination with other agents, and introduce some of the ongoing clinical trials that aim to determine the clinical relevance of bisphosphonates in combination therapy.
Keywords: Zoledronic acid, metastatic bone disease, synergy, bone, Combined Therapies, Bone Disease, Bisphosphonates, advanced malignancies, chemotherapeutic agents, synergy, bone, kidney, prostate, lytic and sclerotic elements, anti-scaling agents, Paget's disease, cholesterol, post-translational modification, osteoclast activity, anti-cancer agents, umour cell apoptosis, MB-231, MCF-7, Hs 578T, alendronate, ibandronate, pamidronate, risedronate, bovine cortical bone slices, cervical intraepithelial neoplasia, lung cancer cells, tumour vascularisation, anti-tumourigenic, osteolytic lesions, non-bone metastases, prostate cancer, zole-dronic acid, T-cell leukemia, regulating tumour growth, COMBINATION THERAPY, invasive cancer, doxorubicin, chemotherapeutic agent, prostate cancer cell lines, mouse breast cancer, intra-cardiac injection, osteolytic bone disease, anatomical, invasive breast cancer, angiogenesis, neo-adjuvant anthracycline, antitumour effects
Current Pharmaceutical Design
Title: Combined Therapies of Bone Disease with Bisphosphonates
Volume: 16 Issue: 27
Author(s): S. P. Syddall, P. D. Ottewell and I. Holen
Affiliation:
Keywords: Zoledronic acid, metastatic bone disease, synergy, bone, Combined Therapies, Bone Disease, Bisphosphonates, advanced malignancies, chemotherapeutic agents, synergy, bone, kidney, prostate, lytic and sclerotic elements, anti-scaling agents, Paget's disease, cholesterol, post-translational modification, osteoclast activity, anti-cancer agents, umour cell apoptosis, MB-231, MCF-7, Hs 578T, alendronate, ibandronate, pamidronate, risedronate, bovine cortical bone slices, cervical intraepithelial neoplasia, lung cancer cells, tumour vascularisation, anti-tumourigenic, osteolytic lesions, non-bone metastases, prostate cancer, zole-dronic acid, T-cell leukemia, regulating tumour growth, COMBINATION THERAPY, invasive cancer, doxorubicin, chemotherapeutic agent, prostate cancer cell lines, mouse breast cancer, intra-cardiac injection, osteolytic bone disease, anatomical, invasive breast cancer, angiogenesis, neo-adjuvant anthracycline, antitumour effects
Abstract: Bisphosphonates are standard treatment for cancer-induced bone disease, a common feature of many advanced malignancies. Traditionally used to inhibit bone turnover and reduce the risk of skeletal-related events, there is now increasing pre-clinical evidence that these agents may also affect tumour burden and disease progression. In particular, combining bisphosphonates with chemotherapeutic agents has been demonstrated to cause substantially increased anti-tumour effects compared to giving the single agents. Clinical studies are in progress to determine whether adding bisphosphonates to standard anti-cancer therapy results in improved outcome for patients. Here we give an overview of the key pre-clinical studies of anti-tumour effects of bisphosphonates, alone and in combination with other agents, and introduce some of the ongoing clinical trials that aim to determine the clinical relevance of bisphosphonates in combination therapy.
Export Options
About this article
Cite this article as:
P. Syddall S., D. Ottewell P. and Holen I., Combined Therapies of Bone Disease with Bisphosphonates, Current Pharmaceutical Design 2010; 16 (27) . https://dx.doi.org/10.2174/138161210793563590
DOI https://dx.doi.org/10.2174/138161210793563590 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Calcium, Vitamin D, and the Extrarenal Vitamin D Hydroxylases in Carcinogenesis
Anti-Cancer Agents in Medicinal Chemistry Targeting Proteasomal Pathways by Dietary Curcumin for Cancer Prevention and Treatment
Current Medicinal Chemistry In Vitro Anticancer Evaluation of Some Synthesized 2H-Quinolinone and Halogenated 2H-Quinolinone Derivatives as Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets Genome-Wide Expression Analysis in Epilepsy: A Synthetic Review
Current Topics in Medicinal Chemistry Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Momordicacharantia: A New Strategic Vision to Improve the Therapy of Endoplasmic Reticulum Stress
Current Pharmaceutical Design Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Application of Selenium Nanoparticles in Localized Drug Targeting for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry <i>Punica granatum</i> Peel Waste - An Underutilized Substrate of Therapeutic Potential: An Overview
Recent Advances in Food, Nutrition & Agriculture Anticancer Compounds from Cyanobacteria and their Implications in Apoptosis
Current Protein & Peptide Science miR-141-3p Promotes the Cisplatin Sensitivity of Osteosarcoma Cell through Targeting the Glutaminase [GLS]-Mediated Glutamine Metabolism
Current Molecular Medicine Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Metal Complexes of Natural Product Like-compounds with Antitumor Activity
Anti-Cancer Agents in Medicinal Chemistry Facile Synthesis of Stereoisomers of the Non-Secosteroidal Ligand LG190178 and their Evaluation Using the Mutant Vitamin D Receptor
Letters in Organic Chemistry Nitric Oxide and the Regulation of Apoptosis in Tumour Cells
Current Pharmaceutical Design Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3
Anti-Cancer Agents in Medicinal Chemistry GRP78 Influences Chemoresistance and Prognosis in Cancer
Current Drug Targets